A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours

被引：0
|
作者：
de Bono, J. S. [1 ,2 ]
Lord, S. [3 ]
Yap, C. [4 ]
Miranda, S. [5 ]
Veal, G. J. [6 ]
Chandran, K. [7 ]
Paschalis, A. [8 ]
Peron, C. [9 ]
Rekowski, J. [10 ]
Gurel, B. [5 ]
Paisley, D. [11 ]
McGuigan, L. [12 ]
Ingram, P. J. [13 ]
Kwek, K. Y. [14 ]
Halbert, G. [12 ]
Westwood, N. B. [12 ]
Griffin, A. E. [11 ]
Kostaras, L. [11 ]
Boyd-Kirkup, J. D. [15 ]
Walter, H. S. [11 ]
机构：
[1] Inst Canc Res, Prostate Canc Targeted Therapies Grp, Sutton, England
[2] Royal Marsden Hosp, Sutton, England
[3] Univ Oxford, Dept Oncol, Oxford, England
[4] ICR Inst Canc Res North Site, Clin Trials Biostat Dept, Sutton, England
[5] ICR Inst Canc Res, Clin Studies Canc Biomarkers, London, England
[6] Newcastle Univ, Newcastle Univ Ctr Canc, Newcastle Upon Tyne, England
[7] Royal Marsden Hosp NHS Fdn, Prostate Canc Targeted Therapies Grp, Sutton, England
[8] ICR Inst Canc Res, Clin Studies, London, England
[9] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford, England
[10] ICR Inst Canc Res, Clin Trials & Stat Unit, London, England
[11] CRUK Canc Res UK, Ctr Drug Dev, London, England
[12] Canc Res UK, Ctr Drug Dev, London, England
[13] Hummingbird Biosci Pte Ltd Temasek Lifesci Labs, Singapore, Singapore
[14] Hummingbird Biosci, Clin Dev, Singapore, Singapore
[15] Hummingbird Biosci Pte Ltd Temasek Lifesci Labs, Res, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1873
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687P
引用
收藏
页码：S479 / S480
页数：2
相关论文
共 50 条
  • [41] Updated analysis of phase I dose-escalation and dose cohort expansion studies of senaparib (IMP4297) in Chinese patients with advanced solid tumours
    Xu, B.
    Junning, C.
    Guo, H.
    Zhang, P.
    Yang, S.
    Zhou, Y.
    Zhang, R.
    Dongmei, J.
    Shen, W.
    Zhang, S.
    Cai, S.
    Tian, Y. E.
    Hsieh, C-Y.
    Xu, C.
    Ma, N.
    Chen, Y.
    Yang, S.
    Zhang, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S491 - S491
  • [42] A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies
    Benoit You
    Anthony Brade
    Joao M. Magalhaes
    Lillian L. Siu
    Amit Oza
    Sonya Lovell
    Lisa Wang
    David W. Hedley
    Leonardo V. Nicacio
    Eric X. Chen
    Investigational New Drugs, 2011, 29 : 996 - 1003
  • [43] A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies
    You, Benoit
    Brade, Anthony
    Magalhaes, Joao M.
    Siu, Lillian L.
    Oza, Amit
    Lovell, Sonya
    Wang, Lisa
    Hedley, David W.
    Nicacio, Leonardo V.
    Chen, Eric X.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 996 - 1003
  • [44] FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study
    Li, Qiao
    Wang, Xian
    Cheng, Ying
    Liu, Yunjiang
    Chang, Jianhua
    Wang, Zhuo
    Wu, Chunjiao
    Wang, Mingxia
    Hui, Ai-Min
    Wu, Zhuli
    Jin, Yongli
    Huang, Xin
    Zhong, Liping
    Diao, Lei
    Zhao, Han
    Xu, Binghe
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985
    Van Herpen, C. M.
    Banerji, U.
    Mommers, E. C.
    Koper, N. P.
    Goedings, P.
    Lopez, J.
    Awada, A.
    Fiebrich, H. B.
    Aftimos, P. G.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S65 - S65
  • [46] First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
    Hassan, Raffit
    Blumenschein, George R., Jr.
    Moore, Kathleen N.
    Santin, Alessandro D.
    Kindler, Hedy L.
    Nemunaitis, John J.
    Seward, Shelly M.
    Thomas, Anish
    Kim, Stella K.
    Rajagopalan, Prabhu
    Walter, Annette O.
    Laurent, Dirk
    Childs, Barrett H.
    Sarapa, Nenad
    Elbi, Cem
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1824 - +
  • [47] Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours
    Fiedler, Walter
    Stoeger, Herbert
    Perotti, Antonella
    Gastl, Guenther
    Weidmann, Jens
    Dietrich, Bruno
    Baumeister, Hans
    Danielczyk, Antje
    Goletz, Steffen
    Salzberg, Marc
    De Dosso, Sara
    ESMO OPEN, 2018, 3 (04)
  • [48] DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors
    Li, Xi
    Yao, Jun
    Qu, Chen
    Luo, Lan
    Li, Bing
    Zhang, Yu
    Zhu, Zhongyuan
    Qiu, Yang
    Hua, Haiqing
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [49] A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
    Richards, Donald A.
    Braiteh, Fadi S.
    Anthony, Stephen Patrick
    Edenfield, Jeff
    Hellerstedt, Beth A.
    Raju, Robert N.
    Conkling, Paul
    Smith, David A.
    Becerra, Carlos
    Cohn, Allen Lee
    Denlinger, Crystal Shereen
    Garbo, Lawrence E.
    Wu, Hillary H.
    Garcia, Agustin
    McDonagh, Charlotte
    Frye, Sasha
    Agresta, Samuel V.
    Moyo, Victor M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345